.After a few years in biotech, Mike Quigley, Ph.D., is going back to the pharma fold, taking up the leading scientific research location at Sanofi.Quigley is going to begin Sept. 30 as the French Big Pharma's main scientific policeman as well as worldwide chief of analysis, Sanofi told Fierce Biotech in an emailed claim.Quigley is actually substituting Frank Nestle, M.D., that left behind Sanofi this springtime amid a worldwide overhaul of the company's R&D system. Nestle, who invested 8 years with the pharma, leapt over to Deerfield Management, where he currently works as a partner on the therapies staff as well as chief executive officer of the firm's curative revelation and advancement operations.
Quigley is going to join Sanofi coming from a San Francisco-based biotech that resides in secrecy, depending on to his LinkedIn profile. He is actually currently noted as the business's founder, head of state as well as CEO.Given that August 2021, Quigley has acted as a project companion at SV Health Investors, a healthcare fund supervisor with current investments in biotechs such as BioAge, Cerevance, Dualitas Therapies as well as Nimbus Therapeutics, and many more. Quigley formerly kept the top location at Dualitas, a biotech that remains in stealth, according to STAT.The future Sanofi forerunner additionally earlier helmed Therini Biography, an immunotherapy biotech working to create procedures for neurodegenerative ailments steered through vascular disorder.Prior to spending the last handful of years in biotech, Quigley possesses an even longer track record in Significant Pharma, most just recently serving as Gilead's senior bad habit president of investigation biology until the summertime of 2021. Prior to that, he clocked in much more than 4 years around several leadership functions at Bristol Myers Squibb and worked as a medical director at Johnson & Johnson's Janssen arm just before that.Sanofi pointed out Quigley's goal in his brand new task will be to "optimize our chance of results with optimal cooperations throughout our organization as well as past, bringing best-in-class development in addition to developing and also sourcing brand new industry-leading skill with a commitment to diversity," according to an internal memorandum acquired by STAT.